Clinical trial
A Multi-center, Randomized, Sham-controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in Subjects With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy
NCT03015623 is registered in ClinicalTrials.gov with Sentien Biotechnologies, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Randomized, Sham-controlled, Double-blind, Ascending-dose Study of Extracorporeal Mesenchymal Stromal Cell Therapy (SBI-101 Therapy) in Subjects With Acute Kidney Injury Receiving Continuous Renal Replacement Therapy
- Lead sponsor
- Sentien Biotechnologies, Inc.
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- June 20, 2017
- Completion date
- December 31, 2021
- Enrollment
- 24 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.